{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.70","value":"-4.2"},{"groupId":"OG001","spread":"5.38","value":"-4.8"},{"groupId":"OG002","spread":"4.69","value":"-4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"79"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.46","value":"-7.3"},{"groupId":"OG001","spread":"6.51","value":"-5.2"},{"groupId":"OG002","spread":"6.10","value":"-6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"53"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.82","value":"-8.0"},{"groupId":"OG001","spread":"7.88","value":"-6.3"},{"groupId":"OG002","spread":"7.39","value":"-7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"37"}],"units":"Participants"}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"104"}],"units":"Participants"}],"description":"Percent change in patients reducing by at least one class level. Class levels: \\<25.0, 25.0 to \\<30.0, ≥ 30.0. Percent change from baseline (BL) =((Post BL value - BL value)/ BL value)\\*100","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"Pasireotide 600 μg"},{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"Pasireotide 900 μg"},{"description":"Patients received pasireotide 600 μg or 900 μg BID","id":"OG002","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Number of patients with available data differed at visits","reportingStatus":"POSTED","timeFrame":"Baseline, week 12, 24 and 48","title":"Percent Change in Cushing's Disease Clinical Signs and Symptoms - Body Mass Index (BMI)","type":"SECONDARY","unitOfMeasure":"percent change in kg/m2"}